EDIT - Editas Medicine, Inc.
| Previous Close | 26.84 |
| Open | 26.86 |
| Bid | 26.76 x 1400 |
| Ask | 28.00 x 1000 |
| Day's Range | 26.37 - 27.06 |
| 52 Week Range | 19.29 - 34.37 |
| Volume | 493,578 |
| Avg. Volume | 940,144 |
| Market Cap | 1.376B |
| Beta (5Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings Date | Feb 25, 2020 - Mar 01, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.00 |
- American City Business Journals
Shares of gene-editing startup Beam jump 40% after upsized IPO
Beam Therapeutics raised 80% more than initially planned when it closed its IPO Thursday, just one week after a neighboring company doubled its market launch goal.
- GuruFocus.com
Andreas Halvorsen Trims Adaptive Biotechnologies Stake
The immune-driven biotech company went public last June Continue reading...
- American City Business Journals
European ruling threatens Broad's CRISPR gene-editing patents
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
- GlobeNewswire
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
In a presentation to investors on Wednesday, January 15, 2020, at 10:30 a.m. PST at the 38th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (EDIT) President and CEO Cynthia Collins will discuss the Company’s progress on developing in vivo and engineered cell medicines and building the leading genomic medicine company.
- GlobeNewswire
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular.
- GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Financial Officer
CAMBRIDGE, Mass., Jan. 10, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly.
- Zacks
Implied Volatility Surging for Editas (EDIT) Stock Options
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
- GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the appointment of Michelle Robertson as the Company’s Chief Financial Officer, and the appointment of Harry Gill in the newly created role of Senior Vice President, Operations, both effective immediately.
- Zacks
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
- GlobeNewswire
Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a.
- Investor's Business Daily
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
- Zacks
Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know
Does Editas Medicine (EDIT) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Simply Wall St.
Editas Medicine (NASDAQ:EDIT) Shareholders Booked A 90% Gain In The Last Three Years
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...
- Insider Monkey
Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- Zacks
Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a (formerly known as Cpf1). The Company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Fla.
- Thomson Reuters StreetEvents
Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
Q3 2019 Editas Medicine Inc Earnings Call
- Zacks
Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher
Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
- American City Business Journals
CRISPR Therapeutics stock jumps on early gene editing data
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
- Zacks
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
- Yahoo Finance Video
Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
